Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Payables (2021 - 2025)

Historic Payables for Rxo (RXO) over the last 5 years, with Q4 2025 value amounting to $539.0 million.

  • Rxo's Payables fell 510.56% to $539.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $539.0 million, marking a year-over-year decrease of 510.56%. This contributed to the annual value of $539.0 million for FY2025, which is 510.56% down from last year.
  • Latest data reveals that Rxo reported Payables of $539.0 million as of Q4 2025, which was down 510.56% from $481.0 million recorded in Q3 2025.
  • In the past 5 years, Rxo's Payables registered a high of $572.0 million during Q3 2024, and its lowest value of $372.0 million during Q1 2024.
  • Over the past 5 years, Rxo's median Payables value was $496.0 million (recorded in 2023), while the average stood at $482.1 million.
  • Over the last 5 years, Rxo's Payables had its largest YoY gain of 3719.81% in 2024, and its largest YoY loss of 2500.0% in 2024.
  • Over the past 5 years, Rxo's Payables (Quarter) stood at $520.0 million in 2021, then dropped by 3.65% to $501.0 million in 2022, then fell by 17.37% to $414.0 million in 2023, then soared by 37.2% to $568.0 million in 2024, then fell by 5.11% to $539.0 million in 2025.
  • Its last three reported values are $539.0 million in Q4 2025, $481.0 million for Q3 2025, and $461.0 million during Q2 2025.